Expression and polymorphisms of T cell immunoglobulin domain and mucin domain protein‑1 in thymoma with or without myasthenia gravis

Zheng,Kai; Xu,Guowu; Lu,Xing; Zhang,Jun; Zhang,Peng

doi:10.3892/ol.2014.2090

Expression and polymorphisms of T cell immunoglobulin domain and mucin domain protein‑1 in thymoma with or without myasthenia gravis

Authors:
- Kai Zheng
- Guowu Xu
- Xing Lu
- Jun Zhang
- Peng Zhang
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital, Heping, Tianjin 300052, P.R. China
Published online on: April 25, 2014 https://doi.org/10.3892/ol.2014.2090
Pages: 317-322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression and association of the single‑nucleotide polymorphism (SNP) ‑1637A/G in the promoter region of the T cell immunoglobulin domain and mucin domain protein‑1 (Tim‑1) gene in patients diagnosed with thymoma with or without myasthenia gravis (MG). The expression of Tim‑1 was detected using the streptavidin peroxidase immunohistochemical staining method on tissues obtained from thymoma patients with (n=58) and without (n=62) MG. The Tim‑1 gene ‑1637A/G polymorphism was detected using the single allele‑specific primer polymerase chain reaction. The positive rate of Tim‑1 expression in thymoma patients with MG was 62.1% (32/58), which was significantly higher compared with that in thymoma patients without MG (33.9%, 21/62) (P=0.002). The genotype frequencies of GG, GA and AA in the ‑1637A/G polymorphism were 0.7931, 0.2069 and 0, respectively, in thymoma patients with MG, and 0.6129, 0.3871 and 0, respectively, in thymoma patients without MG. A significant difference in the genotypes between the thymoma patients with MG and those without MG was found (P=0.031). In addition, a significant difference in allele frequencies between thymoma patients with MG and those without MG (P=0.024) was observed. The high expression of Tim‑1 in thymoma tissues may play an important role in the development of thymoma with MG. The ‑1637A/G polymorphism site of the promoter region in Tim‑1 may be associated with thymoma with MG. These findings provide a basis for further genetic research of thymoma with MG.

View Figures

View References

1	Falkson CB, Bezjak A, Darling G, et al; Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 4:911–919. 2009.
2	Harris K, Elsayegh D, Azab B, Alkaied H and Chalhoub M: Thymoma calcification: Is it clinically meaningful? World J Surg Oncol. 9:952011.
3	Okumura M, Fujii Y, Shiono H, Inoue M, Minami M, Utsumi T, Kadota Y and Sawa Y: Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg. 56:143–150. 2008.
4	Okumura M, Inoue M, Kadota Y, Hayashi A, Tokunaga T, Kusu T, Sawabata N and Shiono H: Biological implications of thymectomy for myasthenia gravis. Surg Today. 40:102–107. 2010.
5	Müller-Hermelink HK and Marx A: Pathological aspects of malignant and benign thymic disorders. Ann Med. 31(Suppl 2): 5–14. 1999.
6	Hong YH, Kwon SB, Kim BJ, et al; Korean Research Group for Neuromuscular Diseases. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 273:10–14. 2008.
7	Romi F: Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis. 2011:4745122011.
8	Vincent A, Palace J and Hilton-Jones D: Myasthenia gravis. Lancet. 357:2122–2128. 2001.
9	Romi F, Bø L, Skeie GO, Myking A, et al: Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol. 128:82–89. 2002.
10	Skeie GO, Bentsen PT, Freiburg A, Aarli JA and Gilhus NE: Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells. Scand J Immunol. 47:76–81. 1998.
11	McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT and DeKruyff RH: Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 2:1109–1116. 2001.
12	McIntire JJ, Umetsu DT and DeKruyff RH: TIM-1, a novel allergy and asthma susceptibility gene. Springer Semin Immunopathol. 25:335–348. 2004.
13	Xu JR, Yang Y, Liu XM, Sun JY and Wang YJ: Polymorphisms of the TIM-1 gene are associated with rheumatoid arthritis in the Chinese Hui minority ethnic population. Genet Mol Res. 11:61–69. 2012.
14	Vega-Carrascal I, Reeves EP and McElvaney NG: The role of TIM-containing molecules in airway disease and their potential as therapeutic targets. J Inflamm Res. 5:77–87. 2012.
15	Abbas AK, Murphy KM and Sher A: Functional diversity of helper T lymphocytes. Nature. 383:787–793. 1996.
16	Ohtani H, Naruse TK, Iwasaki Y, Akari H, Ishida T, Matano T and Kimura A: Lineage-specific evolution of T-cell immunoglobulin and mucin domain 1 gene in the primates. Immunogenetics. 64:669–678. 2012.
17	Seki M, Oomizu S, Sakata KM, et al: Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 127:78–88. 2008.
18	Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L, Ju Y, Zhang L, Sun W and Ma C: Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol. 67:63–70. 2008.
19	Khademi M, Illés Z, Gielen AW, et al: T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol. 172:7169–7176. 2004.
20	Sánchez-Fueyo A, Tian J, Picarella D, et al: Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 4:1093–1101. 2003.
21	Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW and Smyth MJ: Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71:3540–3551. 2011.
22	Sakuishi K, Jayaraman P, Behar SM, Anderson AC and Kuchroo VK: Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32:345–349. 2011.
23	Rennert PD, Ichimura T, Sizing ID, Bailly V, Li Z, Rennard R, McCoon P, Pablo L, Miklasz S, Tarilonte L and Bonventre JV: T cell, Ig domain, mucin domain-2 gene-deficient mice reveal a novel mechanism for the regulation of Th2 immune responses and airway inflammation. J Immunol. 177:4311–4321. 2006.
24	Wang Z, Wang W, Chen Y and Wei D: T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol. 76:54–61. 2012.
25	Chae SC, Park YR, Song JH, Shim SC, Yoon KS and Chung HT: The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population. Immunogenetics. 56:696–701. 2005.
26	Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y and Feinstone SM: Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J. 15:4282–4296. 1996.
27	Feigelstock D, Thompson P, Mattoo P, Zhang Y and Kaplan GG: The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor. J Virol. 72:6621–6628. 1998.
28	Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL and Sanicola M: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 273:4135–4142. 1998.
29	Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK and Umetsu DT: The costimulatory role of TIM molecules. Immunol Rev. 229:259–270. 2009.
30	de Souza AJ, Oriss TB, O’malley KJ, Ray A and Kane LP: TIM-1 is expressed on in vivo-activated T cells and provides a co-stimulatory signal for T cell activation. Proc Natl Acad Sci USA. 102:17113–17118. 2005.
31	Binné LL, Scott ML and Rennert PD: Human TIM-1 associates with the TCR complex and up-regulates T cell activation signals. J Immunol. 178:4342–4350. 2007.
32	Nakae S, Iikura M, Suto H, Akiba H, Umetsu DT, Dekruyff RH, Saito H and Galli SJ: Tim-1 and Tim-3 enhancement of Th2 cytokine production by mast cells. Blood. 110:2565–2568. 2007.
33	Sizing ID, Bailly V, McCoon P, et al: Epitope-dependent effect of anti-murine Tim-1 monoclonal antibodies on T cell activity and lung immune responses. J Immunol. 178:2249–2261. 2007.
34	Kim HY, Eyheramonho MB, Pichavant M, et al: A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. J Clin Invest. 121:1111–1118. 2011.